Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results

Puma Biotechnology (NASDAQ:PBYI) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.04 by $0.15, FiscalAI reports. The firm had revenue of $56.50 million for the quarter, compared to the consensus estimate of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• NERLYNX revenue and demand improved: Q2 net product revenue rose to $53.6 million from $42.0 million in Q1 and $49.2 million a year ago, while U.S. demand increased 8% sequentially and 11% year over year. Management raised full-year 2026 net product revenue guidance to $205–$209 million.
• Puma reported Q2 GAAP net income of $8.2 million, reversing a $3.8 million loss in Q1, and raised full-year net income guidance to $17–$20 million. The company also made its final $11.1 million loan payment and is now debt-free.
• Alisertib development is progressing, with ALISCA-Breast1 enrollment being narrowed to the 40 mg and 50 mg dose groups and ALISCA-Lung1 now enrolling at 70 mg twice daily. Puma expects to start the combination trial ALISCA-Lung02 in Q3 and provide additional trial data in 2027.
• New prescriptions for NERLYNX declined 6% sequentially, and the company expects higher 2026 R&D spending, up 34%–37% year over year, as clinical trials advance. Q3 net income guidance of $2–$2.5 million is substantially below Q2’s result.
• Full-year royalty guidance was reduced to $19–$22 million from $20–$23 million, partly reflecting a possible late-2026 or 2027 reduction in China royalties if generic NERLYNX reaches a specified market-share threshold.

Puma Biotechnology Price Performance

NASDAQ PBYI traded up $0.79 during trading hours on Friday, reaching $8.91. The company’s stock had a trading volume of 683,217 shares, compared to its average volume of 315,645. Puma Biotechnology has a 52 week low of $3.05 and a 52 week high of $9.40. The stock has a market cap of $453.51 million, a P/E ratio of 17.13 and a beta of 1.22. The firm has a fifty day simple moving average of $7.80 and a 200-day simple moving average of $7.18.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Weiss Ratings cut shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, TD Cowen lifted their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.00.

Insider Transactions at Puma Biotechnology

In other news, Director Adrian Senderowicz sold 27,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $194,400.00. Following the completion of the transaction, the director owned 27,000 shares of the company’s stock, valued at approximately $194,400. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alan H. Auerbach sold 44,058 shares of Puma Biotechnology stock in a transaction on Monday, July 6th. The stock was sold at an average price of $8.26, for a total transaction of $363,919.08. Following the transaction, the chief executive officer owned 7,261,671 shares in the company, valued at approximately $59,981,402.46. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 132,028 shares of company stock worth $1,006,711. 22.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $36,000. BNP Paribas Financial Markets lifted its stake in shares of Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,290 shares during the period. Abel Hall LLC bought a new stake in Puma Biotechnology in the fourth quarter valued at approximately $64,000. Dynamic Technology Lab Private Ltd bought a new stake in Puma Biotechnology in the first quarter valued at approximately $66,000. Finally, Ieq Capital LLC acquired a new stake in Puma Biotechnology during the 4th quarter valued at approximately $68,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.